CVnCoV Vaccine (CureVac) Drug Due Diligence Report 2026

This CVnCoV Vaccine (CureVac) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether CVnCoV Vaccine (CureVac) can convert its Prophylactic vaccine, mRNA vaccine profile and SARS-CoV-2 S protein biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	CVnCoV Vaccine (CureVac) (query alias: CVnCoV)
Modality / target	Prophylactic vaccine, mRNA vaccine; SARS-CoV-2 S protein; SARS-CoV-2 S protein inhibitors
Highest global status	Phase 3
Originator	CureVac SE
Active developers	Bayer AG

The MCP disease footprint includes COVID-19, Severe Acute Respiratory Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
EUCTR2021-001735-10-BE	Phase 3	Not Recruiting	620	For the primary objective (safety): •The occurrence of solicited local AEs on each vaccination day and the following 7 days •The occurrence of solicited systemic AEs on each vaccination day and the following 7 days •The occurrence of unsolicited AEs on each vaccination day and the following 28 days •The occurrence of SAEs from first injection up to 28 days after the second injection •The occurrence of SAEs related to study vaccine from first injection up to 28 days after the second injection •The occurrence of AESIs from first injection up to 28 days after the second injection •The occurrence of AESIs related to study vaccine from first injection up to 28 days after the second injection
NCT04860258	Phase 3	Terminated	129	Number of Participants Who Experienced a Solicited Adverse Event (AE) Occurring on the Day of Vaccination and the Following 7 Days After Any Dose
NCT04848467	Phase 3	Withdrawn	Not disclosed	Antibody titers for SARS-CoV-2 receptor binding domain (RBD)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

1243Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Lowest platelet count = 7 x10^9/L ( 3 - 11)

COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older

Phase 2/3; n=39680; evaluation: not stated. Reported fields: Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity = 145 Participants ; Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity: Proportion = 0.364(95.826% CI, 0.299 - 0.433); Vaccine Efficacy = 48.2(95.826% CI, 31.0 - 61.4), P-Value = 0.01600; Number of Participants Who Experienced a First Episode of Virologically-confirmed {Reverse Transcription Polymerase Chain Reaction (RT-PCR) Positive} Case of COVID-19 of Any Severity = 83 Participants

COVID-19 Vaccination Status and Adverse Events Following SARS-CoV-2 Vaccine in Autoimmune Inflammatory Rheumatic Disease (AIRD) Patients: A Single Center Experience

Not Applicable; n=204; evaluation: Negative. Reported fields: Adverse Event: cardiovascular symptoms = 34.8% experienced cardiovascular symptoms after vaccination ; Adverse Event: cardiovascular symptoms = 34.8% experienced cardiovascular symptoms after vaccination ; Adverse Event: cardiovascular symptoms = 34.8% experienced cardiovascular symptoms after vaccination

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

CVnCoV Vaccine (CureVac) addresses COVID-19, Severe Acute Respiratory Syndrome. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Prophylactic vaccine, mRNA vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-01-07	CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV	Phase 2/3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO